ClinicalTrials.gg
CompletedNCT00257686Updated Mar 16, 2010Results posted

Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly Patients

A Phase 3 interventional study of Pitavastatin and Pravastatin in Hypercholesterolemia or Combined Dyslipidemia, sponsored by Kowa Research Europe. Completed at 62 sites in 5 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2010-03-16.

Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
962
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
2nd of 19
962 · median 200
Started
2005
with 4 others
Phase 3
9 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
7 of 19
Kowa Research Europe

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 2nd largest by enrollment, is one of 5 that started in 2005, is one of 9 in phase 3, and was the 4th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of pitavastatin with that of pravastatin in elderly patients

Read the detailed description

Following a wash-out dietary lead-in period, patients will receive either Preavastatin or Pitavastatin during 12 weeks, in order to establish the efficacy of pitavastatin in reducing cholesterol levels.

03

Conditions studied

  • Hypercholesterolemia or Combined Dyslipidemia

Keywords

  • Kowa
  • Hypercholesterolemia
  • combined
  • dyslipidemia
  • elderly
  • pitavastatin
  • NK-104
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females (aged 65 years and older
  • Eligible, able to participate, have given
  • Must have been following a restrictive diet
  • Diagnosis of primary hypercholesterolemia or combined dyslipidemia
  • Serum CK must be less than or equal to 1.5 x ULRR at 2 of 3 permitted evaluations between Week -4 and -1
  • Agree to be available

Exclusion criteria

Exclusion Criteria

  • Homozygous familial hypercholesterolemia
  • Conditions which may cause secondary dyslipidemia
  • Uncontrolled diabetes mellitus ( >8%).
  • Any condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
  • History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury
  • Liver injury
  • Impaired renal function
  • Current obstruction of the urinary tract or difficulty in voiding due to mechanical as well as inflammatory conditions, which is likely to require intervention during the course of the study or is regarded as
  • Serum CK >5 x ULRR without clinical explanation
  • Uncontrolled hypothyroidism defined as TSH >ULRR
  • Any severe acute illness or severe trauma in the last 3 months prior to Visit 1
  • Major surgery, 3 months prior to Visit 1
  • Significant CVD prior to randomization
  • Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response rate of > 100 beats per minute at rest.
  • \<0.25;
  • History of symptomatic cerebrovascular disease
  • Any other conditions at the discretion of the investigator
  • Known infection
  • Poorly controlled or uncontrolled hypertension
  • Prior or current known muscular or neuromuscular disease of any type;
  • Neoplastic disease
  • Drug abuse or continuous consumption of more than 65 mL pure alcohol per day
  • Exposure to any new drug within 30 days of study entry or ingestion of any drug known to be toxic to a major organ system
  • Current or recent use of supplements known to alter lipid metabolism
  • History of to other HMG-CoA reductase inhibitors;
  • Concomitant medication not permitted
  • Resistant to lipid-lowering medications. Known hypersensitivity or intolerance to any lipid lowering agent
  • Excessive obesity
  • Any factor which makes regular clinic attendance in the morning impractical ---Signs of mental dysfunction or other factors likely to limit ability to cooperate with the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
962 participants (actual)

Study arms

  • Experimental
    Pitavastatin 1 mg

    Pitavastatin 1 mg once daily

    Drug: Pitavastatin

  • Active comparator
    Pravastatin 10 mg

    Pravastatin 10 mg once daily

    Drug: Pravastatin

  • Experimental
    Pitavastatin 2 mg

    Pitavastatin 2 mg once daily

    Drug: Pitavastatin

  • Active comparator
    Pravastatin 20 mg

    Pravastatin 20 mg once daily

    Drug: Pravastatin

  • Experimental
    Pitavastatin 4 mg

    Pitavastatin 4 mg once daily

    Drug: Pitavastatin

  • Active comparator
    Pravastatin 40 mg

    Pravastatin 40 mg once daily

    Drug: Pravastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LDL-C

    Percent change from baseline in low density cholesterol (LDL-C)

    Time frame: Baseline to 12 weeks

Secondary outcomes

  1. Percent Change From Baseline in TC

    Percent change from baseline in total cholesterol (TC)

    Time frame: Baseline to 12 weeks

07

Results

Posted Jan 18, 2010

Participant flow

Participant flow — Overall Study
MilestonePitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mg
Started20910822699216104
Safety population20710322496210102
Completed188892088819495
Not completed21191811229

Outcome measures

PrimaryPercent Change From Baseline in LDL-C

Percent change from baseline in low density cholesterol (LDL-C)

Time frame:
Baseline to 12 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in LDL-C
Percent changePitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mg
Percent Change From Baseline in LDL-C-31.43 ± 11.833-22.41 ± 14.051-38.99 ± 13.069-28.83 ± 11.054-44.31 ± 13.695-33.98 ± 14.299
SecondaryPercent Change From Baseline in TC

Percent change from baseline in total cholesterol (TC)

Time frame:
Baseline to 12 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in TC
Percent changePitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mg
Percent Change From Baseline in TC-22.19 ± 8.899-15.34 ± 11.037-26.68 ± 9.429-20.61 ± 8.426-30.75 ± 10.461-24.07 ± 10.907

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 1 mg———
Pravastatin 10 mg———
Pitavastatin 2 mg———
Pravastatin 20 mg———
Pitavastatin 4 mg———
Pravastatin 40 mg———
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mg
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2070/1030/2241/960/2100/102
Acute myocardial infarctionCardiac disorders0/2070/1030/2240/960/2101/102
CholecystitisHepatobiliary disorders0/2070/1030/2240/960/2101/102
CholelithiasisHepatobiliary disorders0/2070/1030/2240/960/2101/102
Bleeding varicose veinVascular disorders0/2070/1030/2240/960/2101/102
Hypertensive crisisVascular disorders0/2070/1030/2240/960/2101/102
Cerebral thrombosisNervous system disorders1/2070/1030/2240/960/2100/102
Myocardial infarctionCardiac disorders0/2070/1030/2240/961/2100/102
Femoral neck fractureInjury, poisoning and procedural complications0/2070/1030/2240/961/2100/102
Intervertebral disc degenerationMusculoskeletal and connective tissue disorders0/2070/1030/2240/961/2100/102
Most frequent other events
Most frequent other events
EventPitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mg
NasopharyngitisInfections and infestations15/2076/10316/2245/9619/2107/102
InfluenzaInfections and infestations7/2076/10316/2246/9619/2107/102
MyalgiaMusculoskeletal and connective tissue disorders3/2073/10311/2242/964/2102/102
ConstipationGastrointestinal disorders10/2075/1036/2244/969/2103/102
NauseaGastrointestinal disorders5/2075/1036/2241/963/2100/102
HeadacheNervous system disorders8/2073/1039/2244/964/2102/102
Back painMusculoskeletal and connective tissue disorders6/2073/1039/2241/963/2102/102
Upper respiratory infectionInfections and infestations3/2074/1032/2241/963/2103/102
FatigueGeneral disorders2/2074/1030/2240/964/2100/102

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mgTotal
<=18 years0000000
Between 18 and 65 years0000000
>=65 years20710322496210102942
Age Continuous
Age Continuous(years)Pitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mgTotal
Mean70.0 ± 4.6070.5 ± 4.6170.5 ± 4.4969.9 ± 4.5170.2 ± 4.1070.2 ± 4.9470.2 ± 4.49
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 1 mgPravastatin 10 mgPitavastatin 2 mgPravastatin 20 mgPitavastatin 4 mgPravastatin 40 mgTotal
Female118541244812142507
Male8949100488960435
08

Study locations

62 sites
  • CCBR A/S
    Aalborg, Denmark
  • Copenhagen University Hospital
    Copenhagen, Denmark
  • Medical Center
    Copenhagen, Denmark
  • CCBR A/S
    Vejle, Denmark
  • Kardiologische Gemeinschaftspraxis Prof. Reifart
    Bad Soden / Taunus, Germany
  • Praxis Dr. Boenninghoff
    Beckum, Germany
  • Klinische Forschung Berlin Mitte
    Berlin, Germany
  • GWT-TUK mbH, Zentrum fur Klinische Studien
    Dresden, Germany
  • Gemeinschaftspraxis Dr. Krause, Th. Menke
    Goch, Germany
  • Klinische Forschung Hamburg
    Hamburg, Germany
  • Innere Medizin I / Medizinische Klinik
    Heidelberg, Germany
  • Gemeinschaftspraxis H. Holz Dr. med, K. W. Klingl
    Lampertheim, Germany
  • ZET-Studien GmbH Leipzing
    Leipzig, Germany
  • Internistische Gemeinschaftspraxis
    Mainz, Germany
  • Praxis Dr. Wachter
    Mannheim, Germany
  • Gemeinschaftspraxis Melcherstaette
    Melcherstaette, Germany
  • Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
    Messkirch, Germany
  • Praxisgemeinschaft im Kleinen Biergrund
    Offenbach/M, Germany
  • Gemeinschaftspraxis Melcherstaette
    Stuhr-Brinkum, Germany
  • Gemeinschaftspraxis Drs. Mockesch
    Weinheim, Germany
  • Intermed Institud Fur Klinische Forschung und Arzn
    Wiesbaden, Germany
  • Gemeinschaftspraxis Dr. Emden, Frank Drewes
    Worpswede, Germany
  • Department of Internal Medicine, Soroka Medical Center
    Beersheva, Israel
  • Department of Internal Medicine A, Rambal Medical Center
    Haifa, Israel
  • Department of Internal Medicine, Wolfson Medical Center
    Holon, Israel
  • Center for Research, Hadassah University Hospital
    Jerusalem Ein Kerem, Israel
  • Meir Hospital
    Kfar Saba, Israel
  • Department of Medicine, Hadassah Medical Center
    Mount Scopus Jerusalem, Israel
  • Department of Internal Medicine, Rivka Sieff Medical Center
    Safed, Israel
  • Institute of Metabolic Diseases
    Tel Aviv, Israel
  • Institue of Lipid & Atherosclerosis Research
    Tel Hashomer, Israel
  • Andromed Oost
    ES Velp, Netherlands
  • Andromed Noord
    Groningen, Netherlands
  • Vasculair Onderzoek Centrum Hoorn
    Hoorn, Netherlands
  • Andromed Leiden
    Leiden, Netherlands
  • Andromed Nijmegen
    Rotterdam, Netherlands
  • Andromed Rotterdam
    Rotterdam, Netherlands
  • Albert Schweitzer ziekenhuis
    Sliedrecht, Netherlands
  • Andromed Breda
    VL Breda, Netherlands
  • Rivierenland Tiel
    WP Tiel, Netherlands
  • Andromed Zoetermeer
    Zoetermeer, Netherlands
  • Albert Schweitzer ziekenhuis
    Zwijndrecht, Netherlands
  • Oldfield Surgery
    Bath, United Kingdom
  • St James's Surgery
    Bath, United Kingdom
  • The Pulteney Practice
    Bath, United Kingdom
  • Birmingham Clinical Research Centre
    Birmingham, United Kingdom
  • Stonehill Medical Center
    Bolton, United Kingdom
  • Chorley Clinical Research Centre
    Chorley, United Kingdom
  • Saltash Health Center
    Cornwall, United Kingdom
  • Gomersal Lane Surgery
    Dronfield, United Kingdom
  • Townhead Research
    Irvine, United Kingdom
  • Crosby Clinical Research Centre
    Liverpool, United Kingdom
  • The Symons Medical Center
    Maidenhead, United Kingdom
  • Manchester Clinical Research Centre
    Manchester, United Kingdom
  • Greenwood Medical Center
    Nottingham, United Kingdom
  • Reading Clinical Research Centre
    Reading, United Kingdom
  • Elm Lane Surgery
    Sheffield, United Kingdom
  • Brook Lane Surgery
    Southampton, United Kingdom
  • Bradford Road Medical Center
    Wiltshire, United Kingdom
  • Rowden Medical Partnership
    Wiltshire, United Kingdom
  • The Porch Surgery
    Wiltshire, United Kingdom
  • The Burns Medical Practice
    Yorkshire, United Kingdom
09

References and documents

Publications

  • Stender S, Budinski D, Gosho M, Hounslow N. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia. Eur J Prev Cardiol. 2013 Feb;20(1):40-53. doi: 10.1177/2047487312451251. Epub 2012 Jun 7. PubMed 22679249 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2005
First posted
Nov 23, 2005
Start
Sep 2005
Primary completionActual
May 2006
CompletionActual
May 2006
Results first posted
Jan 18, 2010
Last update
Mar 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00257686
First posted
Nov 23, 2005
Start date
Sep 2005
Primary completion
May 2006
Completion
May 2006
Results posted
Jan 18, 2010
Last update
Mar 16, 2010

Study contacts

Dragos Budinski, MD
study director · Medical Director

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion